$58.33
+1.77 (+3.13%)
CRSP News7 articles
CRISPR Therapeutics Surges as Key Data Release Looms
CRISPR Therapeutics (CRSP) climbed 6.7% on Tuesday as investors await Friday's CTX310 clinical update. Citizens reaffirmed an $80 target, implying 31% upside.
CRISPR Therapeutics Stock Jumps Ahead of Key CTX310 Data
CRISPR Therapeutics shares climbed 5.8% to $60.38 ahead of CTX310 results due Aug 28. Analysts maintain an $80 target, citing potential as a one-time therapy.
CRISPR Therapeutics Surges 12% on Gene-Editing Sector Rally
CRISPR Therapeutics shares surged 12% in New York trading, buoyed by a sector-wide gene-editing rally and Eli Lilly's $1.9 billion deal with Ascidian Therapeutics.
CRISPR Therapeutics Shares Slide 11.6% as Casgevy Faces Revenue Test
CRISPR Therapeutics shares fell 11.6% Friday as investors weigh Casgevy's market performance and upcoming governance decisions.
Intellia Therapeutics Surges 23% on Promising Phase 3 Data for CRISPR Therapy
Intellia Therapeutics shares surged 23% to $14.92 after Phase 3 data showed lonvo-z reduced hereditary angioedema attacks by up to 91% versus placebo, with FDA filing as the next catalyst.
Intellia's CRISPR Therapy for HAE Nears FDA Filing After Late-Stage Success
Intellia Therapeutics (NTLA) announced its CRISPR therapy lonvo-z cut HAE attacks by 87% vs placebo in a Phase 3 trial, with 62% of patients attack-free. A rolling FDA submission has begun.
Intellia Shares Surge on Eve of Historic CRISPR Phase 3 Data Release
Intellia Therapeutics shares rallied 19.3% after hours Friday as investors await Phase 3 data from its HAELO trial of lonvoguran ziclumeran, an in vivo CRISPR gene-editing therapy for hereditary angioedema.